U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 4

1.
Fig. 4

Fig. 4. From: Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.

An example of the estimated transition point.

Anna E. Kettermann, et al. BJU Int. ;106(9):1284-1292.
2.
Fig. 1

Fig. 1. From: Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.

Selection of the study cohort from the BLSA.

Anna E. Kettermann, et al. BJU Int. ;106(9):1284-1292.
3.
Fig. 2

Fig. 2. From: Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.

Cumulative percentage of men with a PSA transition point: (a) by time before diagnosis; and (b) by age at the transition point. The solid line depicts men who did not and the dotted line depicts those who did die from prostate cancer.

Anna E. Kettermann, et al. BJU Int. ;106(9):1284-1292.
4.
Fig. 3

Fig. 3. From: Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.

Distributions of PSAV levels and PSA at the transition point for men who did and did not die from prostate cancer. (A) Distribution of PSAV; (B) Distribution of PSA levels. Boxes represent the 25th to 75th percentiles (IQR); horizontal lines within boxes are the median values; vertical lines are 1.5 times the IQR (outliers of > 1.5 times the IQR were removed from illustration).

Anna E. Kettermann, et al. BJU Int. ;106(9):1284-1292.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center